Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing their pharmacy benefits. From formularies to compensation, there are choices for employers and plans to
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released the following statement on the Congressional Budget Office’s (CBO) estimate that The INSULIN Act will increase taxpayer spending by approximately $23 billion over 10 years. Pharmacy benefit managers, PBMs,
In its Notice of Proposed Rulemaking for 2019, the Centers for Medicare and Medicaid Services (CMS) has proposed what it characterizes as a clarification of existing policy regarding the requirement that prescription drug plans (PDPs) offer a standard contract to
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued 21 policy solutions supported by America’s pharmacy benefit managers (PBMs) aimed at reducing prescription drug costs for patients and health plan sponsors. PBMs administer prescription drug plans for more than 266 million Americans with
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on a new report from IQVIA Institute for Human Data Science, 2018 and Beyond: Outlook and Turning Points. Key findings from the report include: Rebates and discounts
Court Ruling Finds that ERISA Preempts State PBM Law COURT REJECTS BID TO PREEMPT ERISA…In a unanimous decision, the U.S. Court of Appeals for the Tenth Circuit in PCMA v. Mulready court sustained PCMA’s challenge to four provisions in
The Pharmaceutical Care Management Association recently submitted a letter to the Council of Economic Advisers. Click here for the letter PCMA’s letter includes the following points: 1. The report offers no evidence to back its claim that the drug marketplace
(Washington, D.C.) — A highly consolidated insulin market limits competition and allows dramatic price increases on new and existing brand-name products, according to a new Visante analysis: “Insulins: Managing Costs with Increasing Manufacturer Prices.” The Visante analysis finds that insulin list prices escalated
In case you missed it, PCMA President and CEO JC Scott testified before the U.S. House Education and the Workforce Committee Subcommittee on Health, Employment, Labor, and Pensions. During Scott’s testimony, he highlighted the critical role of pharmacy benefit companies in
©2024 PCMA. All Rights Reserved.
